Lonza and Solvias with a successful long-term

The relationship between Lonza and Solvias (former Ciba-Geigy Central Research) started in the early 90’s with the development and use of Josiphos Ligands in the Lonza Biotin process. Since then many different projects have been jointly developed, scaled up and produced on large- scale. In 1999 Solvias became an independent company and since April 2002 an agreement for research and development enshrines the collaboration.

The long-term collaboration has flourished due to the alignment of the two company cultures, making technology transfers fast and successful. Solvias has become a reliable partner for Lonza in terms of development and transfer of asymmetric reactions to an industrial scale. Lonza is an established large-scale manufacturer of Solvias’ ligands. Lonza and Solvias recognize each others’ value as a partner above all due to the extensive experience both companies have in their particular field of activity. Lonza, having rapid project turn-over, makes use of the services and specific know-how offerings of Solvias as a reliable contract research organisation, in the initial project phases. Solvias, not being a production company, welcomes access to production facilities with a first class track record in production under cGMP and ISO 9001 conditions.

About Lonza Lonza, a chemical and biotechnology company driven by the life sciences, generated sales of CHF 2.18 billion in 2004. Headquartered in Switzerland, Lonza operates 18 production and R&D sites around the world. Its 5700 employees are passionately committed to delivering sustainable value to their customers. Lonza is one of the leading custom manufacturers of chemical intermediates, active ingredients and biopharmaceuticals for the pharmaceutical and agrochemical industries. On the basis of organic chemical, oleochemical and biotechnology platforms, Lonza creates value-added solutions for the nutrition, hygiene & personal care, wood & water treatment and industrial specialty markets. Lonza also offers polymer intermediates, resins and compounds. Further information can be found on our website www.lonza.com.

About Solvias Solvias is an independent technology company providing scientific and technical services and products based on synthesis and analysis. With the comprehensive portfolio, pharmaceutical and biotechnology companies benefit from a wide range of experience in catalysis, asymmetric synthesis, process R+D, polymorphism, salts and crystallisation, and analytical solutions for small molecules and biopharmaceutical from method development to release testing under GMP standards. Solvias is based in Basel, Switzerland and has over 220 highly qualified employees. More detailed information about Solvias, can be found on the website www.solvias.com .

For further information: Media Relations Christine Menz Tel +41 61 316 8253 Fax +41 61 316 9253 christine.menz@lonza.com

Investor Relations Laura Gerber Tel +41 61 316 8347 Fax +41 61 316 8220 laura.gerber@lonza.com

--- ENDE Pressemitteilung Lonza and Solvias with a successful long-term ---

Lonza zählt zu den weltweit führenden Anbietern von Produkten und Dienstleistungen für die Pharma, Gesundheits und Life Sciences-Industrien und ist in der Lage, ihre Kunden vom Forschungsstadium bis hin zur Endproduktion mit ihren Lösungen zu begleiten.

Lonza ist Weltmarktführer in der Produktion und Prozessbegleitung von pharmazeutischen Wirkstoffen, sowohl im chemischen als auch im biotechnologischen Bereich. Biopharmazeutika gehören zu den wichtigsten Wachstumsmotoren der Pharma- und Biotechnologieindustrie.

Lonza verfügt über ausgezeichnetes Know-how in der Herstellung von grossen und kleinen Molekülen, Peptiden, Aminosäuren und in der Nischenproduktion von Bioprodukten, die eine wichtige Rolle bei der Entwicklung neuartiger Arzneimittel und Gesundheitsprodukte spielen. Lonza ist führend in zellbasierter Forschung, in endotoxinen Nachweissystemen sowie in der Zelltherapieproduktion.

Lonza ist ebenfalls eine führende Anbieterin hochwertiger chemischer und biotechnologischer Zwischenprodukte für die Märkte Ernährung, Hygiene, Wasser- und Holzbehandlung, Agro und Körperpflege.

Lonza hat ihren Hauptsitz in Basel, Schweiz, und ist an der SWX Swiss Exchange notiert. Lonza erzielte im Jahr 2006 einen Umsatz von CHF 2,91 Milliarden.

  Lonza Group AG (Firmenporträt)

 Artikel 'Lonza and Solvias with a successful long-term' auf Helpnews.ch